Myocardial dysfunction in rheumatoid arthritis: Epidemiology and pathogenesis

Arthritis Research and Therapy

Volumn 7, Issue 5, 2005, Pages 195-207

  Giles, Jon T ^a   Fernandes, Verônica ^a   Lima, Joao A C ^a   Bathon, Joan M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY ATHEROSCLEROSIS; CYTOKINE PRODUCTION; DIABETES MELLITUS; DISEASE ASSOCIATION; DOPPLER ECHOCARDIOGRAPHY; DRUG EFFICACY; GENE OVEREXPRESSION; HEART FUNCTION TEST; HEART INFARCTION; HEART VENTRICLE REMODELING; HIGH RISK POPULATION; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; INCIDENCE; LIFESTYLE; LUNG DISEASE; MORTALITY; NONHUMAN; OBESITY; OSTEOARTHRITIS; PATHOPHYSIOLOGY; POPULATION DISTRIBUTION; PREVALENCE; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SLEEP APNEA SYNDROME; SMOKING HABIT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; VALVULAR HEART DISEASE;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; COMORBIDITY; CYTOKINES; DISEASE MODELS, ANIMAL; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; IMMUNOGLOBULIN G; INCIDENCE; INFLAMMATION; MALE; MICE; MICE, TRANSGENIC; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, TUMOR NECROSIS FACTOR; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 25144449155     PISSN: 14786354     EISSN: None     Source Type: Journal    
DOI: 10.1186/ar1814     Document Type: Review

References (154)

1. Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S, Linton MF, Raggi P, Stein CM: Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003, 349:2407-2415.
2. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, Crow MK, Schwartz JE, Paget SA, Devereux RB, Salmon JE: Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003, 349:2399-2406.
3. del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A: High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001, 44:2737-2745.
4. Wallberg-Jonsson S, Johansson H, Ohman ML, Rantapaa-Dahlqvist S: Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol 1999, 26:2562-2571.
5. Wolfe F, Freundlich B, Straus WL: Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 2003, 30:36-40.
6. de Lemos JA, Hennekens CH, Ridker PM: Plasma concentration of soluble vascular cell adhesion molecule-1 and subsequent cardiovascular risk. J Am Coll Cardiol 2000, 36:423-426.
7. Wallberg-Jonsson S, Cederfelt M, Rantapaa DS: Hemostatic factors and cardiovascular disease in active rheumatoid arthritis: an 8 year followup study. J Rheumatol 2000, 27:71-75.
8. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH: Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000, 101:1767-1772.
9. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F: Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002, 359:1173-1177.
10. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, Ganiats TG, Goldstein S, Gregoratos G, Jessup, et al.: ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. J Am Coll Cardiol 2001, 38:2101-2113.
11. Massie BM, Shah NB: Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. Am Heart J 1997, 133: 703-712.
12. Schocken DD, Arrieta MI, Leaverton PE, Ross EA: Prevalence and mortality-rate of congestive-heart-failure in the United-States. J Am Coll Cardiol 1992, 20:301-306.
13. Haldeman GA, Croft JB, Giles WH, Rashidee A: Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995. Am Heart J 1999, 137:352-360.
14. Alexander M, Grumbach K, Remy L, Rowell R, Massie BM: Congestive heart failure hospitalizations and survival in California: Patterns according to race ethnicity. Am Heart J 1999, 137: 919-927.
15. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, Murabito JM, Vasan RS: Long-term trends in the incidence of and survival with heart failure. N Engl l Med 2002, 347:1397-1402.
16. Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn BP, Jacobsen SJ: Trends in heart failure incidence and survival in a community-based population. J Am Med Assoc 2004, 292:344-350.
17. Bleumink GS, Knetsch AM, Sturkenboom MCJM, Straus SMJM, Hofman A, Deckers JW, Witteman JC, Stricker BH: Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure: The Rotterdam study. Eur Heart J 2004, 25:1614-1619.
18. Senni M, Tribouilloy CM, Rodeheffer RJ, Jacobsen SJ, Evans JM, Bailey KR, Redfield MM: Congestive heart failure in the community: trends in incidence and survival in a 10-year period. Arch Intern Med 1999, 159:29-34.
19. Ho KKL, Pinsky JL, Kannel WB, Levy D: The epidemiology of heart-failure: the Framingham-study. J Am Coll Cardiol 1993, 22:A6-A13.
20. Senni M, Tribouilloy CM, Rodeheffer RJ, Jacobsen SJ, Evans JM, Bailey KR, Redfield MM: Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation 1998, 98:2282-2289.
21. Mckee PA, Castelli WP, Mcnamara PM, Kannel WB: Natural history of congestive heart failure: Framingham study. N Engl J Med 1971, 285:1441-1446.
22. Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D'Agostino RB, Kannel WB, Murabito JM, Vasan RS, Benjamin EJ, Levy D: Lifetime risk for developing congestive heart failure: The Framingham heart study. Circulation 2002, 106:3068-3072.
23. O'Connell JB: The economic burden of heart failure. Clin Cardiol 2000, 23:6-10.
24. Gabriel SE, Crowson CS, O'Fallon WM: Comorbidity in arthritis. J Rheumatol 1999, 26:2475-2479.
25. Kremers H, Nicola P, Crowson C, Ballman K, Gabriel SE: Risk of heart failure among patients with rheumatoid arthritis. Arthritis Rheum 2003, 48:S706.
26. Nicola PJ, Maradit-Kremers H, Roger VL, Jacobsen SJ, Crowson CS, Ballman KV, Gabriel SE: The risk of congestive heart failure in rheumatoid arthritis: A population-based study over 46 years. Arthritis Rheum 2005, 52:412-420.
27. Wolfe F, Michaud K: Heart failure in rheumatoid arthritis: Rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 2004, 116:305-311.
28. Mutru O, Laakso M, Isomaki H, Koota K: Cardiovascular mortality in patients with rheumatoid-arthritis. Cardiology 1989, 76: 71-77.
29. Nicola P, Crowson CS, Maradit-Kremers H, Gabriel SE: Is congestive heart failure the major contributor of the increased mortality in rheumatoid arthritis? Arthritis Rheum 2004, 50: S674.
30. Remes J, Miettinen H, Reunanen A, Pyorala K: Validity of clinical-diagnosis of heart-failure in primary health-care. Eur Heart J 1991, 12:315-321.
31. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KKL: The progression from hypertension to congestive heart failure. J Am Med Assoc 1996, 275:1557-1562.
32. Cathcart ES, Spodick DH: Rheumatoid heart disease. A study of the incidence and nature of cardiac lesions in rheumatoid arthritis. J Med 1962, 266:959-964.
33. Turner LW, Lansbury J: Low diastolic pressure as a clinical feature of rheumatoid arthritis and its possible etiologic significance. Am J Med Sci 1954, 227:503-508.
34. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, Stampfer MJ, Curhan GC: Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003, 107:1303-1307.
35. McEntegart A, Capell HA, Creran D, Rumley A, Woodward M, Lowe GD: Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology (Oxford) 2001, 40:640-644.
36. Pope JE, Anderson JJ, Felson DT: A metaanalysis of the effects of nonsteroidal antiinflammatory drugs on blood-pressure. Arch Intern Med 1993, 153:477-484.
37. Kannel WB, Abbott RD: Incidence and prognosis of unrecognized myocardial infarction. An update on the Framingham study. N Engl J Med 1984, 311:1144-1147.
38. Elhendy A, Schinkel AFL, van Domburg RT, Bax JJ, Poldermans D: Incidence and predictors of heart failure during long-term follow-up after stress Tc-99m sestamibi tomography in patients with suspected coronary artery disease. J Nucl Cardiol 2004, 11:527-533.
39. Park YB, Ahn CW, Choi HK, Lee SH, In BH, Lee HC, Nam CM, Lee SK: Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound. Arthritis Rheum 2002, 46:1714-1719.
40. Gottdiener JS, Arnold AM, Aurigemma GP, Polak JF, Tracy RP, Kitzman DW, Gardin JM, Rutledge JE, Boineau RC: Predictors of congestive heart failure in the elderly: the cardiovascular health study. J Am Coll Cardiol 2000, 35:1628-1637.
41. He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK: Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med 2001, 161:996-1002.
42. Hakala M, Ilonen J, Reijonen H, Knip M, Koivisto O, Isomaki H: No association between rheumatoid arthritis and insulin dependent diabetes mellitus: An epidemiologic and immunogenetic study. J Rheumatol 1992, 19:856-858.
43. Arnlov J, Lind L, Zethelius B, Andren B, Hales CN, Vessby B, Lithell H: Several factors associated with the insulin resistance syndrome are predictors of left ventricular systolic dysfunction in a male population after 20 years of follow-up. Am Heart J 2001, 142:720-724.
44. Dessein P, Stanwix A, Joffe B: Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: Acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res 2002, 4:R5.
45. Svenson KLG, Pollare T, Lithell H, Hallgren R: Impaired glucose handling in active rheumatoid-arthritis: Relationship to peripheral insulin resistance. Metabolism 1988, 37:125-130.
46. Lebowitz WB: Heart in rheumatoid arthritis (rheumatoid disease): a clinical and pathological study of 62 cases. Ann Intern Med 1963, 58:102.
47. Guedes C, Bianchi-Fior P, Cormier B, Barthelemy B, Rat AC, Boissier MC: Cardiac manifestations of rheumatoid arthritis: A case-control transesophageal echocardiography study in 30 patients. Arthritis Rheum 2001, 45:129-135.
48. Iveson JM, Thadani U, Ionescu M, Wright V: Aortic valve incompetence and replacement in rheumatoid arthritis. Ann Rheum Dis 1975, 34:312-320.
49. Chand EM, Freant LJ, Rubin JW: Aortic valve rheumatoid nodules producing clinical aortic regurgitation and a review of the literature. Cardiovasc Pathol 1999, 8:333-338.
50. Boxt LM: MR imaging of pulmonary hypertension and right ventricular dysfunction. Magn Reson Imaging Clin N Am 1996, 4:307-325.
51. Zitnik RJ, Cooper JAD: Pulmonary-disease due to antirheumatic agents. Clin Chest Med 1990, 11:139-150.
52. Turesson C, Jacobsson LTH: Epidemiology of extra-articular manifestations in rheumatoid arthritis. Scand J Rheumatol 2004, 33:65-72.
53. Radoux V, Menard HA, Begin R, Decary F, Koopman WJ: Airways disease in rheumatoid-arthritis patients: one element of a general exocrine dysfunction. Arthritis Rheum 1987, 30:249-256.
54. Zrour SH, Touzi M, Bejia I, Golli M, Rouatbi N, Sakly N, Younes M, Tabka Z, Bergaoui N: Correlations between high-resolution computed tomography of the chest and clinical function in patients with rheumatoid arthritis: Prospective study in 75 patients. Joint Bone Spine 2005, 72:41-47.
55. Gonzalez-Juanatey C, Testa A, Garcia-Casteo A, Garcia-Porrua C, Llorca J, Ollier WER, Gonzalez-Gay MA: Echocardiographic and Doppler findings in long-term treated rheumatoid arthritis patients without clinically evident cardiovascular disease. Semin Arthritis Rheum 2004, 33:231-238.
56. Dawson JK, Goodson NG, Graham DR, Lynch MP: Raised pulmonary artery pressures measured with Doppler echocardiography in rheumatoid arthritis patients. Rheumatology 2000, 39:1320-1325.
57. Keser G, Capar I, Aksu K, Inal V, Danaoglu Z, Savas R, Oksel F, Tunc E, Kabasakal Y, Kitapcioglu G, Doganavsargil E: Pulmonary hypertension in rheumatoid arthritis. Scand J Rheumatol 2004, 33:244-245.
58. Shahar E, Whitney CW, Redline S, Lee ET, Newman AB, Javier NF, O'Connor GT, Boland LL, Schwartz JE, Samet JM: Sleep-disordered breathing and cardiovascular disease. Cross-sectional results of the sleep heart health study. Am J Resp Crit Care Med 2001, 163:19-25.
59. Peppard PE, Young T, Palta M, Skatrud J: Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000, 342:1378-1384.
60. Chaouat A, Weitzenblum E, Krieger J, Oswald M, Kessler R: Pulmonary hemodynamics in the obstructive sleep apnea syndrome: Results in 220 consecutive patients. Chest 1996, 109: 380-386.
61. Hayashi M, Fujimoto K, Urushibata K, Uchikawa Si, Imamura H, Kubo K: Nocturnal oxygen desaturation correlates with the severity of coronary atherosclerosis in coronary artery disease. Chest 2003, 124:936-941.
62. Minoguchi K, Tazaki T, Yokoe T, Minoguchi H, Watanabe Y, Yamamoto M, Adachi M.: Elevated production of tumor necrosis factor-{alpha} by monocytes in patients with obstructive sleep apnea syndrome. Chest 2004, 126:1473-1479.
63. Redlund-Johnell I: Upper airway obstruction in patients with rheumatoid arthritis and temporomandibular joint destruction. Scand J Rheumatol 1988, 17:273-279.
64. Zamarron C, Maceiras F, Mera A, Gomez-Reino JJ: Effect of the first infliximab infusion on sleep and alertness in patients with active rheumatoid arthritis. Ann Rheum Dis 2004, 63:88-90.
65. Vgontzas AN, Zoumakis E, Lin HM, Bixler EO, Trakada G, Chrousos GP: Marked decrease in sleepiness in patients with sleep apnea by etanercept, a tumor necrosis factor-{alpha} antagonist. J Clin Endocrinol Metab 2004, 89:4409-4413.
66. Symmons DP, Bankhead CR, Harrison BJ, Brennan P, Barrett EM, Scott DG, Silman AJ: Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis: Results from a primary care-based incident case-control study in Norfolk, England. Arthritis Rheum 1997, 40:1955-1961.
67. Kenchaiah S, Evans JC, Levy D, Wilson PWF, Benjamin EJ, Larson MG, Kannel WB, Vasan RS: Obesity and the risk of heart failure. N Engl J Med 2002, 347:305-313.
68. Zhou YT, Grayburn P, Karim A, Shimabukuro M, Higa M, Baetens D, Orci L, Unger RH: Lipotoxic heart disease in obese rats: Implications for human obesity. Proc Natl Acad Sci USA 2000, 97:1784-1789.
69. Gvozdjakova A, Kucharska J, Gvozdjak J: Effect of smoking on the oxidative processes of cardiomyocytes. Cardiology 1992, 81:81-84.
70. Roubenoff R, Roubenoff RA, Cannon JG, Kehayias JJ, Zhuang H, Dawson-Hughes B, Dinarello CA, Rosenberg IH: Rheumatoid cachexia: Cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation. J Clin Invest 1994, 93:2379-2386.
71. Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, Baughman KL, Kasper EK: Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000, 342:1077-1084.
72. Sokoloff L: Cardiac involvement in rheumatoid arthritis and allied disorders: Current concepts. Mod Concepts Cardiovasc Dis 1964, 32:847-850.
73. Abbas A, Byrd BF: Right-sided heart failure due to right ventricular cavity obliteration by rheumatoid nodules. Am J Cardiol 2000, 86:711-712.
74. Ojeda VJ, Stuckey BGA, Owen ET, Walters MNI: Cardiac rheumatoid nodules. Med J Australia 1986, 144:92-93.
75. Peter H, Bernd S, Thomas G, Jurgen S, Ulf M: Fatal outcome of constrictive pericarditis in rheumatoid arthritis. Rheumatol Int 2003, 23:312-314.
76. Yurchak PM, Deshpande V: Case 2-2003: A 60-year-old man with mild congestive heart failure of uncertain cause. N Engl J Med 2003, 348:243-249.
77. Slack JD, Waller B: Acute congestive-heart-failure due to the arthritis of rheumatoid-arthritis: Early diagnosis by endomyocardial biopsy - a case-report. Angiology 1986, 37:477-482.
78. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Levy D: Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction. N Engl J Med 1997, 336: 1350-1355.
79. Drazner MH, Rame JE, Marino EK, Gottdiener JS, Kitzman DW, Gardin JM, Manolio TA, Dries DL, Siscovick DS: Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: The Cardiovascular Health Study. J Am Coll Cardiol 2004, 43: 2207-2215.
80. Lauer MS, Evans JC, Levy D: Prognostic implications of subclinical left-ventricular dilatation and systolic dysfunction in men free of overt cardiovascular-disease (the Framingham heart-study). Am J Cardiol 1992, 70:1180-1184.
81. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991, 325:293-302.
82. Wang TJ, Levy D, Benjamin EJ, Vasan RS: The epidemiology of "asymptomatic" left ventricular systolic dysfunction: Implications for screening. Ann Intern Med 2003, 138:907-916.
83. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D: Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: Prevalence and mortality in a population-based cohort. J Am Coll Cardiol 1999, 33: 1948-1955.
84. Zile MR, Brutsaert DL: New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. Circulation 2002, 105: 1387-1393.
85. Aurigemma GP, Gottdiener JS, Shemanski L, Gardin J, Kitzman D: Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: The Cardiovascular Health Study. J Am Coll Cardiol 2001, 37:1042-1048.
86. Mustonen J, Laakso M, Hirvonen T, Mutru O, Pirnes M, Vainio P, Kuikka JT, Rautio P, Lansimies E: Abnormalities in left-ventricular diastolic function in male-patients with rheumatoid-arthritis without clinically evident cardiovascular-disease. Eur J Clin Invest 1993, 23:246-253.
87. Cindas A, Gokce-Kutsal Y, Tokgozoglu L, Karanfil A: QT dispersion and cardiac involvement in patients with rheumatoid arthritis. Scand J Rheumatol 2002, 31:22-26.
88. Corrao S, Salli L, Arnone S, Scaglione R, Pinto A, Licata G: Echo-Doppler left ventricular filling abnormalities in patients with rheumatoid arthritis without clinically evident cardiovascular disease. Eur J Clin Invest 1996, 26:293-297.
89. Wislowska M, Sypula S, Kowalik I: Echocardiographic findings, 24-hour electrocardiographic Holter monitoring in patients with rheumatoid arthritis according to Steinbrocker's criteria, functional index, value of Waaler-Rose titre and duration of disease. Clin Rheumatol 1998, 17:369-377.
90. Montecucco C, Gobbi G, Perlini S, Rossi S, Grandi AM, Caporali R, Finardi G: Impaired diastolic function in active rheumatoid arthritis. Relationship with disease duration. Clin Exp Rheumatol 1999, 17:407-412.
91. Wislowska M, Sypula S, Kowalik I: Echocardiographic findings and 24-h electrocardiographic Holter monitoring in patients with nodular and non-nodular rheumatoid arthritis. Rheumatol Int 1999, 18:163-169.
92. Di Franco M, Paradiso M, Mammarella A, Paoletti V, Labbadia G, Coppotelli L, Taccari E, Musca A: Diastolic function abnormalities in rheumatoid arthritis. Evaluation by echo Doppler transmitral flow and pulmonary venous flow: relation with duration of disease. Ann Rheum Dis 2000, 59:227-229.
93. Alpaslan M, Onrat E, Evcik D: Doppler echocardiographic evaluation of ventricular function in patients with rheumatoid arthritis. Clin Rheumatol 2003, 22:84-88.
94. Levendoglu F, Temizhan A, Ugurlu H, Ozdemir A, Yazici M: Ventricular function abnormalities in active rheumatoid arthritis: a Doppler echocardiographic study. Rheumatol Int 2004, 24:141-146.
95. Zile MR, Baicu CF, Gaasch WH: Diastolic heart failure: Abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004, 350:1953-1959.
96. Petrie MC, Hogg K, Caruana L, McMurray JJV: Poor concordance of commonly used echocardiographic measures of left ventricular diastolic function in patients with suspected heart failure but preserved systolic function: Is there a reliable echocardiographic measure of diastolic dysfunction? Heart 2004, 90:511-517.
97. Vasan RS, Benjamin EJ, Larson MG, Leip EP, Wang TJ, Wilson PWF, Levy D: Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: The Framingham heart study. J Am Med Assoc 2002, 288:1252-1259.
98. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, Wolf PA, Vasan RS: Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004, 350:655-663.
99. Yasuda M, Yasuda D, Tomooka K, Nobunaga M: Plasma concentration of human atrial natriuretic hormone in patients with connective-tissue diseases. Clin Rheumatol 1993, 12:231-235.
100. Shichiri M, Miyasaka N, Hirata Y, Ando K, Marumo F: Appearance of beta-human atrial-natriuretic-peptide in collagen disease. J Endocrinol 1991, 130:159-161.
101. Vasan RS, Beiser A, D'Agostino RB, Levy D, Selhub J, Jacques PF, Rosenberg IH, Wilson PW: Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction. J Am Med Assoc 2003, 289:1251-1257.
102. Sundstrom J, Sullivan L, Selhub J, Benjamin EJ, D'Agostino RB, Jacques PF, Rosenberg IH, Levy D, Wilson PW, Vasan RS: Relations of plasma homocysteine to left ventricular structure and function: The Framingham heart study. Eur Heart J 2004, 25: 523-530.
103. Welch GN, Loscalzo J: Homocysteine and atherothrombosis. N Engl J Med 1998, 338:1042-1050.
104. Wallberg-Jonsson S, Cvetkovic JT, Sundqvist KG, Lefvert AK, Rantapaa-Dahlqvst S: Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis. J Rheumatol 2002, 29:875-882.
105. Yxfeldt A, Wallberg-Jonsson S, Hultdin J, Rantapaa-Dahlqvist S: Homocysteine in patients with rheumatoid arthritis in relation to inflammation and B-vitamin treatment. Scand J Rheumatol 2003, 32:205-210.
106. Prodanowich S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS: Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005, 52:262-267.
107. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL: Cytokines and cytokine receptors in advanced heart failure: An analysis of the cytokine database from the vesnarinone trial (VEST). Circulation 2001, 103:2055-2059.
108. Kubota T, Miyagishima M, Alvarez RJ Jr, Kormos R, Rosenblum WD, Demetris AJ, Semigran MJ, Dec GW, Holubkov R, McTiernan CF, et al.: Expression of proinflammatory cytokines in the failing human heart: Comparison of recent-onset and end-stage congestive heart failure. J Heart Lung Transplant 2000, 19:819-824.
109. Levine B, Kalman J, Mayer L, Fillit HM, Packer M: Elevated circulating levels of tumor-necrosis-factor in severe chronic heart-failure. N Engl J Med 1990, 323:236-241.
110. Rauchhaus M, Doehner W, Francis DP, Kemp M, Nicbauer J, Volk HD, Coats AJS, Anker SD: Cytokine parameters predict increased mortality in patients with chronic heart failure. Eur Heart J 2000, 21:233.
111. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL: Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1996, 27:1201-1206.
112. Torre-Amione G, Kapadia S, Lee J, Durand JB, Bies RD, Young JB, Mann DL: Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 1996, 93:704-711.
113. Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, Sawyer DB, Levy D, Wilson PW, D'Agostino RB: Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: The Framingham heart study. Circulation 2003, 107:1486-1491.
114. Cesari M, Penninx BWJH, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, Rubin SM, Ding J, Simonsick EM, Harris TB, Pahor M: Inflammatory markers and onset of cardiovascular events: Results from the Health ABC study. Circulation 2003, 108:2317-2322.
115. Birks EJ, Latif N, Owen V, Bowles C, Felkin LE, Mullen AJ, Khaghani A, Barton PJ, Polak JM, Pepper JR: Quantitative myocardial cytokine expression and activation of the apoptotic pathway in patients who require left ventricular assist devices. Circulation 2001, 104:233-240.
116. Birks EJ, Burton PBJ, Owen V, Mullen AJ, Hunt D, Banner NR, Barton PJ, Yacoub MH: Elevated tumor necrosis factor-{alpha} and interleukin-6 in myocardium and serum of malfunctioning donor hearts. Circulation 2000, 102:352-358.
117. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Genovese MC, Wasko MC, Moreland LW, Weaver AL, et al.: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000, 343:1586-1593.
118. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000, 343:1594-1602.
119. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ: A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999, 340:253-259.
120. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK: Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum 2003, 48:35-45.
121. Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, Collins AJ: Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005, 16:489-495.
122. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT: Randomized, double-blind, placebo-controlled, pilot trial of Infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure: Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial. Circulation 2003, 107:3133-3140.
123. Mann DL, McMurray JJV, Packer M, Swedberg K, Borer JS, Colucci WS, Djian J, Drexler H, Feldman A, Kober L, et al.: Targeted anticytokine therapy in patients with chronic heart failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004, 109:1594-1602.
124. Khanna D, McMahon M, Furst DE: Anti-tumor necrosis factor a therapy and heart failure: What have we learned and where do we go from here? Arthritis Rheum 2004, 50:1040-1050.
125. Bernatsky S, Hudson M, Suissa S: Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology (Oxford) 2005, 44:677-680.
126. Hochreiter CA, Carter J, Herrold EMM, Warren MS, Whitmore J, Borer JS: Treatment with Etanercept (Enbrel) does not affect left ventricular ejection fraction (LVEF) in patients with chronic heart failure. Arthritis Rheum 2003, 48:s120.
127. Chung MK, Gulick TS, Rotondo RE, Schreiner GF, Lange LG: Mechanism of cytokine inhibition of beta-adrenergic agonist stimulation of cyclic AMP in rat cardiac myocytes. Impairment of signal transduction. Circ Res 1990, 67:753-763.
128. Krown KA, Page MT, Nguyen C, Zechner D, Gutierrez V, Comstock K, Glembotski CC, Quintana PJ, Sabbadini RA: Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest 1996, 98:2854-2865.
129. Suffredini AF, Fromm RE, Parker MM, Brenner M, Kovacs JA, Wesley RA, Parrillo JE: The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 1989, 321:280-287.
130. Bozkurt B, Kribbs SB, Clubb FJ, Michael LH, Didenko VV, Hornsby PJ, Seta Y, Oral H, Spinale FG, Mann DL: Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation 1998, 97:1382-1391.
131. Kubota T, McTiernan CF, Frye CS, Demetris AJ, Feldman AM: Cardiac-specific overexpression of tumor necrosis factor-alpha causes lethal myocarditis in transgenic mice. J Am Coll Cardiol 1997, 29:29165.
132. Bryant D, Becker L, Richardson J, Shelton J, Franco F, Peshock R, Thompson M, Giroir B: Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-{alpha}. Circulation 1998, 97:1375-1381.
133. Li X, Moody MR, Engel D, Walker S, Clubb FJ Jr, Sivasubramanian N, Mann DL, Reid MB: Cardiac-specific overexpression of tumor necrosis factor-{alpha} causes oxidative stress and contractile dysfunction in mouse diaphragm. Circulation 2000, 102:1690-1696.
134. Kadokami T, Frye C, Lemster B, Wagner CL, Feldman AM, McTiernan CF: Anti-tumor necrosis factor-{alpha} antibody limits heart failure in a transgenic model. Circulation 2001, 104:1094-1097.
135. Li YY, Feng YQ, Kadokami T, McTiernan CF, Draviam R, Watkins SC, Feldman AM: Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy. Proc Natl Acad Sci USA 2000, 97:12746-12751.
136. Sivasubramanian N, Coker ML, Kurrelmeyer KM, MacLellan WR, Demayo FJ, Spinale FG, Mann DL: Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor. Circulation 2001, 104:826-831.
137. Cohn JN, Ferrari R, Sharpe N: Cardiac remodeling - concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol 2000, 35:569-582.
138. Wilson EM, Gunasinghe HR, Coker ML, Sprunger P, Lee-Jackson D, Bozkurt B, Deswal A, Mann DL, Spinale FG: Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. J Card Fail 2002, 8:390-398.
139. Coker ML, Jolly JR, Joffs C, Etoh T, Holder JR, Bond BR, Spinale FG: Matrix metalloproteinase expression and activity in isolated myocytes after neurohormonal stimulation. Am J Physiol Heart Circ Physiol 2001, 281:H543-H551.
140. Coker ML, Thomas CV, Clair MJ, Hendrick JW, Krombach RS, Galis ZS, Spinale FG: Myocardial matrix metalloproteinase activity and abundance with congestive heart failure. Am J Physiol 1998, 274:H1516-H1523.
141. Altieri P, Brunelli C, Garibaldi S, Nicolino A, Ubaldi S, Spallarossa P, Olivotti L, Rossettin P, Barsotti A, Ghigliotti G: Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure. Eur J Clin Invest 2003, 33:648-656.
142. Gao CQ, Sawicki G, Suarez-Pinzon WL, Csont T, Wozniak M, Ferdinandy M, Schulz R: Matrix metalloproteinase-2 mediates cytokine-induced myocardial contractile dysfunction. Cardiovasc Res 2003, 57:426-433.
143. Roten L, Nemoto S, Simsic J, Coker ML, Rao V, Baicu S, Defreyte G, Soloway PJ, Zile MR, Spinale FG: Effects of gene deletion of the tissue inhibitor of the matrix metalloproteinase-type 1 (TIMP-1) on left ventricular geometry and function in mice. J Mol Cell Cardiol 2000, 32:109-120.
144. Peterson JT, Hallak H, Johnson L, Li H, O'Brien PM, Sliskovic DR, Bocan TM, Coker ML, Etoh T, Spinale FG: Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation 2001, 103:2303-2309.
145. Li YY, Kadokami T, Wang P, McTiernan CF, Feldman AM: MMP inhibition modulates TNF-alpha transgenic mouse phenotype early in the development of heart failure. Am J Physiol Heart Circ Physiol 2002, 282:H983-H989.
146. Sivasubramanian N, Coker ML, Kurrelmeyer KM, MacLellan WR, Demayo FJ, Spinale FG, Mann DL: Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor. Circulation 2001, 104:826-831.
147. Berry MF, Woo YJ, Pirolli TJ, Bish LT, Moise MA, Burdick JW, Morine KJ, Jayasankar V, Gardner TJ, Sweeney HL: Administration of a tumor necrosis factor inhibitor at the time of myocardial infarction attenuates subsequent ventricular remodeling. J Heart Lung Transplant 2004, 23:1061-1068.
148. Hein S, Arnon E, Kostin S, Schonburg M, Elsasser A, Polyakova V, Bauer EP, Klovekorn WP, Schaper J: Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: Structural deterioration and compensatory mechanisms. Circulation 2003, 107:984-991.
149. Kubota T, Bounoutas GS, Miyagishima M, Kadokami T, Sanders VJ, Bruton C, Robbins PD, McTiernan CF, Feldman AM: Soluble tumor necrosis factor receptor abrogates myocardial inflammation but not hypertrophy in cytokine-induced cardiomyopathy. Circulation 2000, 101:2518-2525.
150. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, et al.: A metalloproteinase disintegrin that releases tumour-necrosis
151. Diwan A, Dibbs Z, Nemoto S, DeFreitas G, Carabello BA, Sivasubramanian N, Wilson EM, Spinale FG, Mann DL: Targeted overexpression of noncleavable and secreted forms of tumor necrosis factor provokes disparate cardiac phenotypes. Circulation 2003, 109:262-268.
152. Dibbs ZI, Diwan A, Nemoto S, DeFreitas G, Abdellatif M, Carabello BA, Spinale FG, Feuerstein G, Sivasubramanian N, Mann DL: Targeted overexpression of transmembrane tumor necrosis factor provokes a concentric cardiac hypertrophic phenotype. Circulation 2003, 108:1002-1008.
153. Satoh M, Nakamura M, Saitoh H, Satoh H, Maesawa C, Segawa I, Tashiro A, Hiramori K: Tumor necrosis factor-{alpha} converting enzyme and tumor necrosis factor-{alpha} in human dilated cardiomyopathy. Circulation 1999, 99:3260-3265.
154. Satoh M, Nakamura M, Satoh H, Saitoh H, Segawa I, Hiramori K: Expression of tumor necrosis factor-alpha-converting enzyme and tumor necrosis factor-alpha in human myocarditis. J Am Coll Cardiol 2000, 36:1288-1294.